Book Value per Share: Kiniksa Pharmaceuticals (KNSA)

Graphic logo of Kiniksa Pharmaceuticals (KNSA)

Kiniksa Pharmaceuticals (KNSA) is a biopharmaceutical player developing drugs for rare cardiovascular and immune disorders. This market valuation chart reflects the price action of the asset, which is currently 8.45. The business relies on the development of targeted therapy for inflammatory processes to capture monopoly niches, while the firm's environmental policy remains standard, focusing on basic laboratory waste control.

Kiniksa Pharmaceuticals, Ltd. (KNSA): Share Book Value from 07/04/2022 to 10/28/2026

kiniksa.com - analytical breakdowns and key metrics (KNSA)

- price and consensus price forecast:
Price Chart Kiniksa Pharmaceuticals Ltd|KNSA - Analyst Median Target
- market capitalization data:
Market Capitalization Kiniksa Pharmaceuticals|KNSA - Enterprise Value
- book capitalization data:
Net Assets per Single Share Kiniksa|KNSA - Net Asset Value|Market Capitalization to Book Value Ratio kiniksa.com|KNSA - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Kiniksa Pharmaceuticals|KNSA - Long-Term Debt to Capital|Short-Term Debt to Equity Kiniksa|KNSA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Kiniksa Pharmaceuticals|KNSA - Company Long-Term Liabilities|Company Short-Term Debts Kiniksa
Fundamental company valuation:Kiniksa Pharmaceuticals Ltd - KNSA
Manufactured products of Kiniksa

Kiniksa Pharmaceuticals (KNSA) dominates the niche of rare cardiovascular inflammation therapy due to the uniqueness of the drug Arcalyst. The bps_co metric reflects the residual value of a single share upon the full liquidation of all liabilities using equity. By analyzing the dynamics of book value per share via GURU.Markets tools, an investor separates the real value of assets from market noise. Growth in this metric confirms the capitalization of the business through stable cash flows. A steady trend here serves as a defensive barrier against an unjustified decline in quotes.

Competitors of Kiniksa Pharmaceuticals (KNSA)

Net Assets per Single Share ARGX (Argenx)|BNTX - Net Assets per Share|ABVX: Book Value per Share|ADMA (admabiologics.com) - Book Value per Share|Net Assets per Single Share Protagonist PTGX|Share Book Value Immunovant Inc|Grifols Group (GRFS) - Book Value per Share|Accounting Value of a Share Adaptive Biotechnologies Inc. (ADPT)|Book Value per Share CLDX (Celldex Therapeutics)|auriniapharma.com - Book Value per Share|Net Assets per Single Share BioCryst Pharmaceuticals (BCRX)|VERA: Accounting Value of a Share|DNTH (Dianthus Pharma) - Net Assets per Single Share|Pharvaris Pharma (PHVS) - Accounting Value per Share|ABCL (AbCellera Biologics Inc) - Book Value per Share|Book Value per Share tourmalinebio.com (TRML)|Precigen (PGEN) - Accounting Value per Share|Accounting Value of a Share Pharming Group NV (PHAR)|Book Value per Share NKTR|Upstream Pharma - Net Assets per Share|ZBIO: Net Assets per Single Share|IMNM: Accounting Value per Share|GOSS (Gossamer Bio) - Net Assets per Single Share|Accounting Value per Share KalVista Pharma|SEPN (Septerna Corp) - Accounting Value per Share|Book Value per Share PVLA|Net Assets per Single Share Savara Inc. SVRA|Equity per Share rigel.com (RIGL)|ANAB: Book Value per Share|Astria Therapeutics Inc - Net Asset Value per Share|enGene Bio - Net Assets per Single Share|RAPT - Book Value per Share|aerovatetx.com - Book Value per Share|ACRS (aclaristx.com) - Net Assets per Share|Net Assets per Single Share Kyverna Therapeutics, Inc. (KYTX)|Equity per Share Tiziana Life Sciences Ltd.|CABA (Cabaletta Bio, Inc) - Book Value per Share|Net Assets per Share VTYX (Ventyx Biosciences, Inc)|Net Assets per Single Share THTX (Theratechnologies Inc.)|avalotx.com - Book Value per Share|Net Assets per Single Share ELDN (Eledon Pharmaceuticals, Inc.)|AGEN - Net Assets per Share|CLYM: Book Value per Share|Book Value per Share Zura Bio Ltd|ATYR - Accounting Value per Share|Accounting Value of a Share ADAG|IMA - Net Assets per Single Share|Share Book Value shattucklabs.com (STTK)|Book Value per Share Equillium|Accounting Value of a Share Connect Biopharma Holdings CNTB|Immunic Inc - Book Value per Share|ATRA: Book Value per Share|Net Assets per Single Share inflarx.de IFRX|XFOR (X4 Pharmaceuticals Inc.) - Accounting Value of a Share|Net Assets per Single Share ACET|Accounting Value per Share Celularity Corp|Book Value per Share INMB|Book Value per Share barinthusbio.com (BRNS)|Kezar Life Sciences, Inc. - Book Value per Share|Accounting Value per Share SAB Biotherapeutics Inc. SABS|AKTX (Akari Therapeutics plc) - Book Value per Share|Enlivex Therapeutics (ENLV) - Net Asset Value per Share|QTTB: Accounting Value per Share|Book Value per Share geovax.com|Edesa Biotech (EDSA) - Accounting Value per Share|Book Price of a Share iBio Inc|CARM (Carisma Therapeutics) - Book Value per Share|Net Assets per Share XTL Bio (XTLB)|Bolt Biotherapeutics, Inc. - Book Value per Share|Accounting Value per Share HCW Biologics, Inc. HCWB|Aptevo - Book Value per Share|AIM: Book Value per Share|aditxt.com (ADTX) - Net Assets per Single Share|GRI (GRI Bio Corporation) - Net Assets per Single Share|XRTX: Net Assets per Single Share|Net Assets per Share HIND|Net Assets per Single Share REVB|Book Value per Share INDP (Indaptus Therapeutics Inc)|SCNI - Net Assets per Single Share|CalciMedica Inc - Equity per Share|Net Assets per Single Share AFMD (Affimed Therapeutics)|ALLK - Net Assets per Share|HOOK: Book Value per Share|IGMS (IGM Biosciences) - Book Value per Share|Net Assets per Single Share iTeos ITOS|Share Book Value Ocean Biomedical Corp|TC Biopharm (TCBP) - Book Value per Share|Accounting Value of a Share thirdharmonicbio.com (THRD)